Market Closed -
Nasdaq
16:30:00 2024-05-09 EDT
|
5-day change
|
1st Jan Change
|
0.5415
USD
|
-3.49%
|
|
-4.83%
|
-48.92%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,673
|
114
|
4.81
|
3.335
|
4.256
|
-
|
-
|
Enterprise Value (EV)
1 |
18,673
|
114
|
4.81
|
3.335
|
4.256
|
4.256
|
4.256
|
P/E ratio
|
-
|
-3.18
x
|
-0.06
x
|
-0.23
x
|
-0.19
x
|
-0.24
x
|
0.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
32.3
x
|
1.91
x
|
1.5
x
|
2.61
x
|
0.31
x
|
0.07
x
|
EV / Revenue
|
-
|
32.3
x
|
1.91
x
|
1.5
x
|
2.61
x
|
0.31
x
|
0.07
x
|
EV / EBITDA
|
-
|
-
|
-0.2
x
|
-0.31
x
|
-0.22
x
|
-0.57
x
|
-1.08
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,257
|
101
|
534
|
3,146
|
7,585
|
-
|
-
|
Reference price
2 |
2,984
|
1,128
|
9.000
|
1.060
|
0.5611
|
0.5611
|
0.5611
|
Announcement Date
|
21-03-15
|
22-03-31
|
23-03-30
|
24-03-15
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3.531
|
2.523
|
2.231
|
1.63
|
13.61
|
59.79
|
EBITDA
1 |
-
|
-
|
-24.22
|
-10.72
|
-19.7
|
-7.504
|
-3.957
|
EBIT
1 |
-
|
-19.87
|
-24.22
|
-10.72
|
-19.7
|
-7.567
|
-4.181
|
Operating Margin
|
-
|
-562.71%
|
-959.91%
|
-480.52%
|
-1,208.25%
|
-55.61%
|
-6.99%
|
Earnings before Tax (EBT)
1 |
-
|
-29.15
|
-24.21
|
-10.63
|
-19.8
|
-7.669
|
-4.284
|
Net income
1 |
0.0568
|
-29.89
|
-25.09
|
-10.63
|
-16.91
|
-11.18
|
29
|
Net margin
|
-
|
-846.37%
|
-994.12%
|
-476.39%
|
-1,037.24%
|
-82.13%
|
48.5%
|
EPS
2 |
-
|
-355.2
|
-139.4
|
-4.690
|
-3.025
|
-2.335
|
17.35
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-15
|
22-03-31
|
23-03-30
|
24-03-15
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.635
|
0.6031
|
0.2075
|
0.2794
|
1.433
|
0.7896
|
0.4905
|
0.4354
|
0.515
|
0.4
|
0.4
|
0.4
|
0.45
|
0.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-2.007
|
-4.803
|
-7.055
|
-6.163
|
-6.201
|
-2.561
|
-2.294
|
-2.707
|
-3.156
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-122.72%
|
-796.35%
|
-3,400.58%
|
-2,206.31%
|
-432.58%
|
-324.36%
|
-467.7%
|
-621.83%
|
-612.72%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-10.04
|
-0.9509
|
-7.923
|
-9.856
|
-5.478
|
-2.192
|
-2.239
|
-2.691
|
-3.517
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-10.84
|
-1.667
|
-7.999
|
-9.898
|
-5.522
|
-2.196
|
-2.236
|
-2.69
|
-3.504
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-662.88%
|
-276.35%
|
-3,855.64%
|
-3,543.09%
|
-385.22%
|
-278.12%
|
-455.88%
|
-617.75%
|
-680.41%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-108.0
|
-14.40
|
-57.60
|
-61.56
|
-74.28
|
-2.080
|
-0.9800
|
-0.8700
|
-1.370
|
-0.9000
|
-0.7250
|
-0.7100
|
-0.6900
|
-0.6000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-31
|
22-05-12
|
22-08-11
|
22-11-14
|
23-03-30
|
23-05-15
|
23-08-11
|
23-11-09
|
24-03-15
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-15
|
22-03-31
|
23-03-30
|
24-03-15
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -48.92% | 4.26M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|